Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes ...

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

Biocon Biologics will supply Insulin Aspart drug substance to Civica, who will use the drug substance to produce Insulin Aspart drug product. Sandra Levy 3/13/2025 ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE ...